yahoo_financeOriginal article
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Phase 1positiveNMRA-215Positive
AI Analysis
Summary
Neumora Therapeutics reported favorable toxicology results for NMRA-215 with plans to advance the program into clinical development in 2026.
Clinical Trial Data
Phase
preclinical
Primary Endpoint
Met
Outcome Details
Favorable toxicology results reported
Importance:5/10
Sentiment:
0.70
drug developmentpreclinical datatoxicologyclinical advancement
Related Companies
Read the original article
Published by yahoo_finance on July 27, 2026 11:00 AM